Stockscreener 앱 받기
55.23
2.68%
1.44
시간 외 거래:
55.23
전일 마감가:
$53.79
열려 있는:
$53.4
하루 거래량:
1.47M
Relative Volume:
0.83
시가총액:
$5.30B
수익:
$1.64B
순이익/손실:
$121.85M
주가수익비율:
35.86
EPS:
1.54
순현금흐름:
$-480.40M
1주 성능:
+1.10%
1개월 성능:
-25.47%
6개월 성능:
-56.62%
1년 성능:
-52.23%
1일 변동 폭
$52.80
$56.11
1주일 범위
$52.80
$56.34
52주 변동 폭
$48.01
$173.25
사렙타 테라퓨틱스 Stock (SRPT) Company Profile
명칭
Sarepta Therapeutics Inc
전화
617-274-4000
주소
215 FIRST STREET, CAMBRIDGE, MA
SRPT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
55.23 | 5.30B | 1.64B | 121.85M | -480.40M | 1.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
사렙타 테라퓨틱스 Stock (SRPT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-11 | 개시 | Wells Fargo | Overweight |
| 2025-04-02 | 업그레이드 | H.C. Wainwright | Sell → Neutral |
| 2025-03-31 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2024-11-27 | 재확인 | Needham | Buy |
| 2024-11-25 | 개시 | H.C. Wainwright | Sell |
| 2024-11-07 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | 개시 | Jefferies | Buy |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-07-29 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-05-31 | 개시 | Piper Sandler | Overweight |
| 2024-05-28 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-01-31 | 개시 | BMO Capital Markets | Outperform |
| 2023-12-13 | 재개 | Citigroup | Buy |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-11-21 | 개시 | Wedbush | Outperform |
| 2023-10-31 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-06-23 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-04-26 | 개시 | SMBC Nikko | Outperform |
| 2023-04-04 | 개시 | Citigroup | Buy |
| 2023-03-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | 재확인 | BTIG Research | Buy |
| 2022-12-16 | 업그레이드 | UBS | Neutral → Buy |
| 2022-04-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-01-05 | 재확인 | Needham | Buy |
| 2021-12-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-11-05 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-09-15 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-08-05 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-04-26 | 재개 | Credit Suisse | Neutral |
| 2021-01-12 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-01-11 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-01-08 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2021-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | 개시 | Berenberg | Hold |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-08-20 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | 개시 | Mizuho | Buy |
| 2019-11-01 | 개시 | Guggenheim | Buy |
| 2019-08-21 | 재확인 | Needham | Buy |
| 2019-07-09 | 재확인 | Morgan Stanley | Overweight |
| 2019-07-01 | 재확인 | RBC Capital Mkts | Outperform |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-11 | 재확인 | Credit Suisse | Outperform |
| 2018-10-12 | 개시 | Bernstein | Outperform |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-26 | 재확인 | RBC Capital Mkts | Outperform |
| 2018-09-14 | 재개 | BofA/Merrill | Buy |
| 2018-09-06 | 개시 | Credit Suisse | Outperform |
| 2018-08-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | 재확인 | Robert W. Baird | Outperform |
| 2018-06-20 | 재확인 | Needham | Buy |
| 2018-06-19 | 재확인 | H.C. Wainwright | Buy |
모두보기
사렙타 테라퓨틱스 주식(SRPT)의 최신 뉴스
ALDX Investors Have Opportunity to Join Aldeyra Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
SRPT Investors Have Opportunity to Join Sarepta Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost - Investor's Business Daily
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta - Bluefield Daily Telegraph
Netflix To Rally More Than 55%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
Piper Sandler Cuts Price Target for Sarepta (SRPT) Amid Elevidys Sales Concerns | SRPT Stock News - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sarepta Thera - NatLawReview.com
Sarepta (SRPT) Price Target Lowered by BofA Ahead of Q1 Earnings | SRPT Stock News - GuruFocus
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Not Doing Enough For Some Investors As Its Shares Slump 27% - simplywall.st
Sarepta Therapeutics’ (SRPT) Neutral Rating Reiterated at HC Wainwright - Defense World
Cancer Retains Top Spots In Alliance Deal Volume, Value - insights.citeline.com
Exploring 3 High Growth Tech Stocks In The US Market - Yahoo Finance
BofA Adjusts Price Target on Sarepta Therapeutics to $157 From $179, Keeps Buy Rating - marketscreener.com
FDA OKs trial of SRP-9005 gene therapy for LGMD type 2C - Muscular Dystrophy News
Sarepta loses CMO to RNA editing upstart; Another wave of personnel moves at Dyne - Endpoints News
Sarepta Therapeutics (NASDAQ:SRPT investor one-year losses grow to 54% as the stock sheds US$166m this past week - Yahoo Finance
Lobbying Update: $320,000 of SAREPTA THERAPEUTICS INC. lobbying was just disclosed - Nasdaq
Sarepta Therapeutics: Buy Rating Affirmed on Promising LGMD Program Progress and Regulatory Advancements - TipRanks
SRPT Provides Pipeline Updates on Rare Muscular Disorder Therapies - Zacks Investment Research
Sarepta (SRPT) Advances Gene Therapy Trials for Muscular Dystrop - GuruFocus
FDA clears Sarepta to proceed with LGMD gene therapy trials By Investing.com - Investing.com Nigeria
Sarepta Therapeutics Announces Pipeline Progress For Multiple Limb-Girdle Muscular Dystrophy Programs - marketscreener.com
Sarepta Therapeutics Announces Pipeline Progress for Multiple Li - GuruFocus
FDA clears Sarepta to proceed with LGMD gene therapy trials - Investing.com
Sarepta Therapeutics (SRPT) Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy Programs - StreetInsider
Sarepta Therapeutics Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy Programs - itemonline.com
Sarepta Expands Rare Disease Pipeline: FDA Green Light for New LGMD Trial - Stock Titan
Trump health policy uncertainty sends biotech sector into deeper slump - MarketScreener
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by O Shaughnessy Asset Management LLC - Defense World
Morgan Stanley Lowers Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $182.00 - Defense World
Wells Fargo Initiates Coverage of Sarepta Therapeutics (BMV:SRPT) with Overweight Recommendation - Nasdaq
SRPT Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm - PR Newswire
Wells Fargo Initiates Coverage of Sarepta Therapeutics (SRPT) with Overweight Recommendation - Nasdaq
Wells Fargo Initiates Coverage of Sarepta Therapeutics (SRPT) wi - GuruFocus
Sarepta stock wins bullish view at Wells Fargo (SRPT:NASDAQ) - Seeking Alpha
Sarepta (SRPT) Price Target Cut by Morgan Stanley Ahead of Earni - GuruFocus
Cns Specific Antisense Oligonucleotide Market Is Booming - openPR.com
Wells Fargo Starts Sarepta (SRPT) with Overweight Rating, Targets $115 | SRPT Stock News - GuruFocus
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Zacks Research Issues Pessimistic Forecast for SRPT Earnings - Defense World
Sarepta Therapeutics (SRPT) Sees Price Target Reduction by Gugge - GuruFocus
The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb - Yahoo Finance
Q1 EPS Estimate for Sarepta Therapeutics Reduced by Analyst - Defense World
Around the Helix: Cell and Gene Therapy Company Updates – April 9, 2025 - CGTLive®
Independent DMC Concludes that Risk-Benefit Ratio for Sarepta’s DMD Gene Therapy Elevidys Remains Favorable - CGTLive®
NASDAQ: SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm - Business Wire
Sarepta (SRPT) Shares Fall Over 6% Following EMA Clinical Hold - GuruFocus
Sarepta (SRPT) Seeks Continuation of Elevidys Trials Amid Safety Review - GuruFocus
Sarepta Therapeutics (NASDAQ:SRPT) versus Cellectar Biosciences (NASDAQ:CLRB) Financial Analysis - Defense World
Sarepta Therapeutics Stock Falls as Some Trials Halted After Patient Death - MSN
NASDAQ: SRPT Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm - Financial Content
사렙타 테라퓨틱스 (SRPT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.15%
4.32%
자본화:
|
볼륨(24시간):